Press Release

Licensing Agreement for the Development, Manufacturing and Commercialization of BBI-4000April 1, 2015

Tokyo and Miami, FL, April 1, 2015 -Kaken Pharmaceutical Co., Ltd. (“Kaken”) and Brickell Biotech, Inc. (“Brickell”; Headquarters: Florida, U.S.A.) concluded an agreement on March 31, 2015 concerning the exclusive licensing and joint development of BBI-4000, for which Brickell is conducting a Phase 2b clinical trial in the U.S. for patients with primary focal hyperhidrosis.

 

Kaken acquired the rights to the exclusive development, manufacture, and marketing in Japan and certain other Asian countries with the conclusion of this agreement. Kaken will make an upfront payment to Brickell under the agreement. Kaken will also make milestone payments in progress on development and pay royalties on sales. Both companies will work together on global research and development in the future.

 

About Primary Focal Hyperhidrosis
A condition that involves heavy sweating on the palms, soles, armpits, and other places caused by heat, stress, or occurring without such causes, and interferes with daily life and work.

 

About BBI-4000
BBI-4000 is a new molecular entity that belongs to a class of drugs called “anticholinergics,” which exert their effect by blocking the action of acetylcholine, a molecule that transmits signals within the nervous system that are responsible for a range of bodily functions, including the activation of sweat glands. Soft-anticholinergics such as BBI-4000 exert their action topically and are rapidly metabolized into a considerably less active metabolite when reaching the blood system; this may allow effective doses to be used without the limiting systemic side effects associated with other drugs in this class.

 

About Brickell Biotech
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of skin diseases. Founded by a team of experienced pharmaceutical executives, Brickell’s development strategy includes: rapidly and cost effectively developing product candidates; executing strategic partnership; maintaining a diversified product portfolio that addresses unmet medical needs; and leveraging professional relationships with thought leaders and contract research organizations in the pharmaceutical industry. For more information, visit www.brickellbio.com.

Back to list